Rocket Pharmaceuticals, Inc. (RCKT) stock
RCKTNasdaqPharmaceutical PreparationsFiscal year ends December 31
$2.11+0.00 (0.00%)
Close on Nov 18, 2026Market cap $231.62MP/E –Yield –
Rocket Pharmaceuticals total assets
Total assets on the balance sheet at the end of each period.
Rocket Pharmaceuticals's total assets was $423.10M at Jun 30, 2026. For fiscal 2025 it was $330.45M, down 37.4% from the year before. Over ten years it grew 11.3% a year on average. The highest annual figure on record is $590.82M in fiscal 2020.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $330.45M | -37.4% |
| FY2024 | Dec 31, 2024 | $527.70M | -6.8% |
| FY2023 | Dec 31, 2023 | $566.34M | +2.6% |
| FY2022 | Dec 31, 2022 | $551.81M | +11.0% |
| FY2021 | Dec 31, 2021 | $497.02M | -15.9% |
| FY2020 | Dec 31, 2020 | $590.82M | +58.8% |
| FY2019 | Dec 31, 2019 | $372.12M | +48.1% |
| FY2018 | Dec 31, 2018 | $251.31M | +1147.4% |
| FY2017 | Dec 31, 2017 | $20.15M | -84.5% |
| FY2016 | Dec 31, 2016 | $129.65M | +14.4% |
| FY2015 | Dec 31, 2015 | $113.32M | +1952.9% |
| FY2014 | Dec 31, 2014 | $5.52M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $423.10M | +0.5% |
| Q1 FY2026 | Mar 31, 2026 | $285.41M | -39.4% |
| Q4 FY2025 | Dec 31, 2025 | $330.45M | -37.4% |
| Q3 FY2025 | Sep 30, 2025 | $368.03M | -6.5% |
| Q2 FY2025 | Jun 30, 2025 | $420.98M | -5.7% |
| Q1 FY2025 | Mar 31, 2025 | $471.07M | -5.7% |
| Q4 FY2024 | Dec 31, 2024 | $527.70M | -6.8% |
| Q3 FY2024 | Sep 30, 2024 | $393.69M | -34.2% |
| Q2 FY2024 | Jun 30, 2024 | $446.41M | -3.3% |
| Q1 FY2024 | Mar 31, 2024 | $499.44M | -3.0% |
| Q4 FY2023 | Dec 31, 2023 | $566.34M | +2.6% |
| Q3 FY2023 | Sep 30, 2023 | $598.76M | +43.5% |
| Q2 FY2023 | Jun 30, 2023 | $461.78M | +6.9% |
| Q1 FY2023 | Mar 31, 2023 | $514.76M | +11.9% |
| Q4 FY2022 | Dec 31, 2022 | $551.81M | +11.0% |
| Q3 FY2022 | Sep 30, 2022 | $417.27M | -21.3% |
| Q2 FY2022 | Jun 30, 2022 | $431.85M | -19.3% |
| Q1 FY2022 | Mar 31, 2022 | $460.15M | -20.2% |
| Q4 FY2021 | Dec 31, 2021 | $497.02M | -15.9% |
| Q3 FY2021 | Sep 30, 2021 | $530.24M | +58.0% |
| Q2 FY2021 | Jun 30, 2021 | $535.15M | +51.6% |
| Q1 FY2021 | Mar 31, 2021 | $576.48M | +54.7% |
| Q4 FY2020 | Dec 31, 2020 | $590.82M | +58.8% |
| Q3 FY2020 | Sep 30, 2020 | $335.50M | +11.9% |
| Q2 FY2020 | Jun 30, 2020 | $353.07M | +14.4% |
| Q1 FY2020 | Mar 31, 2020 | $372.75M | +53.9% |
| Q4 FY2019 | Dec 31, 2019 | $372.12M | +48.1% |
| Q3 FY2019 | Sep 30, 2019 | $299.91M | +53.8% |
| Q2 FY2019 | Jun 30, 2019 | $308.72M | +48.7% |
| Q1 FY2019 | Mar 31, 2019 | $242.14M | +11.5% |
| Q4 FY2018 | Dec 31, 2018 | $251.31M | +1147.4% |
| Q3 FY2018 | Sep 30, 2018 | $194.98M | +86.3% |
| Q2 FY2018 | Jun 30, 2018 | $207.57M | +86.9% |
| Q1 FY2018 | Mar 31, 2018 | $217.17M | +84.2% |
| Q4 FY2017 | Dec 31, 2017 | $20.15M | -84.5% |
| Q3 FY2017 | Sep 30, 2017 | $104.66M | -25.3% |
| Q2 FY2017 | Jun 30, 2017 | $111.07M | – |
| Q1 FY2017 | Mar 31, 2017 | $117.92M | – |
| Q4 FY2016 | Dec 31, 2016 | $129.65M | – |
| Q3 FY2016 | Sep 30, 2016 | $140.14M | – |
See a number that looks wrong?